What is the consensus among healthcare professionals about cannabis use in PMR?
Posted
Updated
Author: Julia Sutton, MSc
Reviewed by: Dr. Clarissa Morton, PharmD
The use of cannabis in polymyalgia rheumatica management remains an area of active discussion. Understanding the healthcare consensus about cannabis for PMR can guide both patients and clinicians in making informed decisions.
Healthcare providers tend to exercise caution, balancing potential benefits against uncertainties in long-term outcomes and safety.
Clinician Opinion
Many clinicians express measured clinician opinion, acknowledging anecdotal benefits but emphasising the limited evidence base. Most advocate for cannabis as an adjunct rather than a first-line therapy.
Prescriber Attitudes
Prescriber attitudes vary widely, with some open to supervised use in refractory cases, while others remain cautious due to regulatory and safety considerations.
Expert Views on PMR
Expert views on PMR generally support further research. Specialists often recommend participation in clinical trials or closely monitored therapeutic trials before routine use is considered.
Overall, the healthcare consensus about cannabis for PMR leans towards cautious optimism. While clinician opinion, prescriber attitudes, and expert views on PMR acknowledge potential benefits, the emphasis remains on evidence-based practice and patient safety, highlighting the need for ongoing research and formal guidelines.
If you’re exploring cannabis treatment options for polymyalgia rheumatica, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.
For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and polymyalgia rheumatica.
Written by
Julia Sutton, MSc
Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.
All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.
Reviewed by
Dr. Clarissa Morton, PharmD
Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.
All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.
